Charles River Laboratories International, Inc. (CRL) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 43.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,310 shares of the medical research company’s stock after selling 4,914 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Charles River Laboratories International were worth $638,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. UBS Asset Management Americas Inc. boosted its position in shares of Charles River Laboratories International by 0.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 89,008 shares of the medical research company’s stock worth $8,006,000 after acquiring an additional 228 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Charles River Laboratories International by 28.5% during the 1st quarter. Schroder Investment Management Group now owns 17,128 shares of the medical research company’s stock worth $1,535,000 after acquiring an additional 3,804 shares in the last quarter. OppenheimerFunds Inc. boosted its position in shares of Charles River Laboratories International by 9.1% during the 1st quarter. OppenheimerFunds Inc. now owns 4,713 shares of the medical research company’s stock worth $424,000 after acquiring an additional 394 shares in the last quarter. FMR LLC boosted its position in shares of Charles River Laboratories International by 39.7% during the 1st quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock worth $223,806,000 after acquiring an additional 707,612 shares in the last quarter. Finally, Advantus Capital Management Inc boosted its position in shares of Charles River Laboratories International by 3.1% during the 1st quarter. Advantus Capital Management Inc now owns 6,065 shares of the medical research company’s stock worth $546,000 after acquiring an additional 183 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

CRL has been the subject of several analyst reports. Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories International in a research report on Monday. Jefferies Group LLC reaffirmed a “buy” rating and set a $120.00 price objective on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price objective for the company in a research report on Thursday, August 10th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price objective for the company. Finally, BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Six analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $102.05.

TRADEMARK VIOLATION NOTICE: This article was first posted by BBNS and is the property of of BBNS. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://baseballnewssource.com/markets/tudor-investment-corp-et-al-reduces-stake-in-charles-river-laboratories-international-inc-crl/1701757.html.

Shares of Charles River Laboratories International, Inc. (CRL) traded up 0.200% during mid-day trading on Wednesday, hitting $114.458. The company had a trading volume of 11,718 shares. The stock’s 50-day moving average is $108.17 and its 200-day moving average is $98.26. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $114.58. The stock has a market cap of $5.45 billion, a price-to-earnings ratio of 30.160 and a beta of 0.96.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.20 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

In related news, insider David Ross Smith sold 2,552 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total transaction of $171,239.20. Following the sale, the insider now owns 11,671 shares of the company’s stock, valued at $783,124.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total value of $399,640.00. Following the sale, the insider now directly owns 20,424 shares in the company, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,699 shares of company stock worth $1,892,393. 2.20% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.